KYNTRA BIO, INC. KYNB
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
3/9
Piotroski F — financial health
-45.53
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $6.4M | $183.5M | — | -$4.8M | -$30.0M |
| 2024 | $29.6M | -$47.6M | — | -$138.3M | -$205.1M |
| 2023 | $46.8M | -$284.2M | — | -$317.5M | -$183.7M |
| 2022 | $140.7M | -$293.7M | — | -$149.7M | -$1.5M |
| 2021 | $235.3M | -$290.0M | — | -$87.4M | $229.1M |
| 2020 | $176.3M | -$189.3M | — | $77.6M | $441.4M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Wettig Thane | CEO | 2026-06-06 | Tax withheld | 198 | $6.71 |
| DeLucia David | Chief Financial Officer | 2026-06-06 | Tax withheld | 52 | $6.71 |
| Wettig Thane | CEO | 2026-05-14 | Buy | 2,800 | $7.09 |
| Wettig Thane | CEO | 2026-03-06 | Tax withheld | 277 | $6.84 |
| DeLucia David | Chief Financial Officer | 2026-03-06 | Tax withheld | 60 | $6.84 |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -45.53 (distress)
- Working capital / assets 0.584
- Retained earnings / assets -14.265
- EBIT / assets -0.384
- Equity / liabilities -0.261
Source: SEC EDGAR filings · CIK 0000921299 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.